865 research outputs found
Computational accountability in MAS organizations with ADOPT
This work studies how the notion of accountability can play a key role in the design and realization of distributed systems that are open and that involve autonomous agents that should harmonize their own goals with the organizational goals. The socio–technical systems that support the work inside human companies and organizations are examples of such systems. The approach that is proposed in order to pursue this purpose is set in the context of multiagent systems organizations, and relies on an explicit specification of relationships among the involved agents for capturing who is accountable to whom and for what. Such accountability relationships are created along with the agents’ operations and interactions in a shared environment. In order to guarantee accountability as a design property of the system, a specific interaction protocol is suggested. Properties of this protocol are verified, and a case study is provided consisting of an actual implementation. Finally, we discuss the impact on real-world application domains and trace possible evolutions of the proposal
Rethinking the patient: using Burden of Treatment Theory to understand the changing dynamics of illness
<b>Background</b> In this article we outline Burden of Treatment Theory, a new model of the relationship between sick people, their social networks, and healthcare services. Health services face the challenge of growing populations with long-term and life-limiting conditions, they have responded to this by delegating to sick people and their networks routine work aimed at managing symptoms, and at retarding - and sometimes preventing - disease progression. This is the new proactive work of patient-hood for which patients are increasingly accountable: founded on ideas about self-care, self-empowerment, and self-actualization, and on new technologies and treatment modalities which can be shifted from the clinic into the community. These place new demands on sick people, which they may experience as burdens of treatment.<p></p>
<b>Discussion</b> As the burdens accumulate some patients are overwhelmed, and the consequences are likely to be poor healthcare outcomes for individual patients, increasing strain on caregivers, and rising demand and costs of healthcare services. In the face of these challenges we need to better understand the resources that patients draw upon as they respond to the demands of both burdens of illness and burdens of treatment, and the ways that resources interact with healthcare utilization.<p></p>
<b>Summary</b> Burden of Treatment Theory is oriented to understanding how capacity for action interacts with the work that stems from healthcare. Burden of Treatment Theory is a structural model that focuses on the work that patients and their networks do. It thus helps us understand variations in healthcare utilization and adherence in different healthcare settings and clinical contexts
School-based self-management interventions for asthma among primary school children:A systematic review
First estimates of the global and regional incidence of neonatal herpes infection
Background Neonatal herpes is a rare but potentially devastating condition with an estimated 60% fatality rate without
treatment. Transmission usually occurs during delivery from mothers with herpes simplex virus type 1 (HSV-1) or
type 2 (HSV-2) genital infection. However, the global burden has never been quantifi ed to our knowledge. We
developed a novel methodology for burden estimation and present fi rst WHO global and regional estimates of the
annual number of neonatal herpes cases during 2010–15.
Methods We applied previous estimates of HSV-1 and HSV-2 prevalence and incidence in women aged 15–49 years to
2010–15 birth rates to estimate infections during pregnancy. We then applied published risks of neonatal HSV
transmission according to whether maternal infection was incident or prevalent with HSV-1 or HSV-2 to generate
annual numbers of incident neonatal infections. We estimated the number of incident neonatal infections by
maternal age, and we generated separate estimates for each WHO region, which were then summed to obtain global
estimates of the number of neonatal herpes infections.
Findings Globally the overall rate of neonatal herpes was estimated to be about ten cases per 100 000 livebirths,
equivalent to a best-estimate of 14 000 cases annually roughly (4000 for HSV-1; 10 000 for HSV-2). We estimated that
the most neonatal herpes cases occurred in Africa, due to high maternal HSV-2 infection and high birth rates. HSV-1
contributed more cases than HSV-2 in the Americas, Europe, and Western Pacifi c. High rates of genital HSV-1
infection and moderate HSV-2 prevalence meant the Americas had the highest overall rate. However, our estimates
are highly sensitive to the core assumptions, and considerable uncertainty exists for many settings given sparse
underlying data.
Interpretation These neonatal herpes estimates mark the fi rst attempt to quantify the global burden of this rare but
serious condition. Better collection of primary data for neonatal herpes is crucially needed to reduce uncertainty and
refi ne future estimates. These data are particularly important in resource-poor settings where we may have
underestimated cases. Nevertheless, these fi rst estimates suggest development of new HSV prevention measures
such as vaccines could have additional benefi ts beyond reducing genital ulcer disease and HSV-associated HIV
transmission, through prevention of neonatal herpes
Global and Regional Estimates of Prevalent and Incident Herpes Simplex Virus Type 1 Infections in 2012
Herpes simplex virus type 1 (HSV-1) commonly causes orolabial ulcers, while HSV-2 commonly causes genital ulcers. However, HSV-1 is an increasing cause of genital infection. Previously, the World Health Organization estimated the global burden of HSV-2 for 2003 and for 2012. The global burden of HSV-1 has not been estimated.We fitted a constant-incidence model to pooled HSV-1 prevalence data from literature searches for 6 World Health Organization regions and used 2012 population data to derive global numbers of 0-49-year-olds with prevalent and incident HSV-1 infection. To estimate genital HSV-1, we applied values for the proportion of incident infections that are genital.We estimated that 3709 million people (range: 3440-3878 million) aged 0-49 years had prevalent HSV-1 infection in 2012 (67%), with highest prevalence in Africa, South-East Asia and Western Pacific. Assuming 50% of incident infections among 15-49-year-olds are genital, an estimated 140 million (range: 67-212 million) people had prevalent genital HSV-1 infection, most of which occurred in the Americas, Europe and Western Pacific.The global burden of HSV-1 infection is huge. Genital HSV-1 burden can be substantial but varies widely by region. Future control efforts, including development of HSV vaccines, should consider the epidemiology of HSV-1 in addition to HSV-2, and especially the relative contribution of HSV-1 to genital infection
Recommended from our members
Increased Responsiveness to Novelty is Associated with Successful Cognitive Aging
The animal literature suggests that exposure to more complex, novel environments promotes neurogenesis and cognitive performance in older animals. Studies in humans indicate that participation in intellectually stimulating activities may serve as a buffer against mental decline and help to sustain cognitive abilities. Here, we show that across old adults, increased responsiveness to novel events (as measured by viewing duration and the size of the P3 event-related potential) is strongly linked to better performance on neuropsychological tests, especially those involving attention/executive functions. Cognitively high performing old adults generate a larger P3 response to visual stimuli than cognitively average performing adults. These results suggest that cognitively high performing adults successfully manage the task by appropriating more resources and that the increased size of their P3 component represents a beneficial compensatory mechanism rather than less efficient processing
Antitumor activity and safety of the PARP inhibitor rucaparib in patients with high grade ovarian carcinoma and a germline or somatic BRCA1 or BRCA2 mutation: integrated analysis of data from Study 10 and ARIEL2
Objective:
An integrated analysis was undertaken to characterize the antitumor activity and safety profile of the oral poly(ADP-ribose) polymerase inhibitor rucaparib in patients with relapsed high-grade ovarian carcinoma (HGOC).
Methods:
Eligible patients from Study 10 (NCT01482715) and ARIEL2 (NCT01891344) who received a starting dose of oral rucaparib 600 mg twice daily (BID) with or without food were included in these analyses. The integrated efficacy population included patients with HGOC and a deleterious germline or somatic BRCA1 or BRCA2 (BRCA1/2) mutation who received at least two prior chemotherapies and were sensitive, resistant, or refractory to platinum-based chemotherapy. The primary endpoint was investigator-assessed confirmed objective response rate (ORR). Secondary endpoints included duration of response (DOR) and progression-free survival (PFS). The integrated safety population included patients with HGOC who received at least one dose of rucaparib 600 mg BID, irrespective of BRCA1/2 mutation status and prior treatments.
Results:
In the efficacy population (n = 106), ORR was 53.8% (95% confidence interval [CI], 43.8–63.5); 8.5% and 45.3% of patients achieved complete and partial responses, respectively. Median DOR was 9.2 months (95% CI, 6.6–11.6). In the safety population (n = 377), the most frequent treatment-emergent adverse events (AEs) were nausea, asthenia/fatigue, vomiting, and anemia/hemoglobin decreased. The most common grade ≥ 3 treatment-emergent AE was anemia/hemoglobin decreased. Treatment-emergent AEs led to treatment interruption, dose reduction, and treatment discontinuation in 58.6%, 45.9%, and 9.8% of patients, respectively. No treatment-related deaths occurred.
Conclusions:
Rucaparib has antitumor activity in advanced BRCA1/2-mutated HGOC and a manageable safety profile
RESEARCH AND REVIEWS: JOURNAL OF PHARMACOGNOSY AND PHYTOCHEMISTRY Safety and Efficacy of Herbal Ointment formulated with Methanolic Extract of Mikania cordata as Treatment for Acute Superficial Injury
ABSTRACT The main objective of this study is to investigate the safety and efficacy of herbal ointment formulated with methanolic extract of Mikania cordata as Treatment for acute superficial injury. Ointment was prepared by fusion method using emulsifying ointment as base. The formulation was then tested for its physicochemical properties like loss of drying, pH, spreadability, extrudability, together with diffusion study and gave a satisfactory result. The prepared ointment was also stable at 4 0 C, 25 0 C and 37 0 C. Further, the formulation was evaluated for its antibacterial activity against Staphylococcus aureus, Pseudomonas sp., Bacillus sp., by agar diffusion method by using Mupirocin (6%w/w) as a standard. The formulation showed significant (p<0.01) activity against Staphylococcus areus and Bacillus sp compared to Mupirocin ointment which showed a significant (p<0.01) activity against Pseudomonas sp and E. coli. Antioxidant activity of the extract through reducing power assay showed that the scavenging activity of the formulation increased with increase in concentration due to the presence of flavonoids and tannins. The dermatological effect of the herbal ointment was carried out by applying a considerable amount of the ointment on the skin surface area of ten healthy individuals in phase I clinical trial and showed a satisfactory result with no allergic or irritation reaction. Evaluation of the healing potency of the extract was carried out on twenty individuals with acute superficial injuries in phase II clinical trial and showed a significant (p<0.01) wound treatment index of 5.43±0.37 and a percentage reduction index of 28.26±4.14. The standard treatment drug mupirocin also showed a significant difference (p<0.01) with a treatment index of 4.47±0.26cm and a wound percentage reduction index of 21.68±3.76. Paired sample correlations showed no significant difference (p>0.01) between those treated with M. cordata and those treated with mupirocin. Overall result of this study reveals that the herbal ointment of Mikania cordata is safe and as pharmacologically competent as Mupirocin and can be used as treatment for superficial injuries
Early and Middle Holocene Hunter-Gatherer Occupations in Western Amazonia: The Hidden Shell Middens
We report on previously unknown early archaeological sites in the Bolivian lowlands, demonstrating for the first time early and middle Holocene human presence in western Amazonia. Multidisciplinary research in forest islands situated in seasonally-inundated savannahs has revealed stratified shell middens produced by human foragers as early as 10,000 years ago, making them the oldest archaeological sites in the region. The absence of stone resources and partial burial by recent alluvial sediments has meant that these kinds of deposits have, until now, remained unidentified. We conducted core sampling, archaeological excavations and an interdisciplinary study of the stratigraphy and recovered materials from three shell midden mounds. Based on multiple lines of evidence, including radiocarbon dating, sedimentary proxies (elements, steroids and black carbon), micromorphology and faunal analysis, we demonstrate the anthropogenic origin and antiquity of these sites. In a tropical and geomorphologically active landscape often considered challenging both for early human occupation and for the preservation of hunter-gatherer sites, the newly discovered shell middens provide evidence for early to middle Holocene occupation and illustrate the potential for identifying and interpreting early open-air archaeological sites in western Amazonia. The existence of early hunter-gatherer sites in the Bolivian lowlands sheds new light on the region's past and offers a new context within which the late Holocene "Earthmovers" of the Llanos de Moxos could have emerged. © 2013 Lombardo et al
Patient Work and Treatment Burden in Type 2 Diabetes: A Mixed-Methods Study.
OBJECTIVE: To use quantitative and qualitative methods to characterize the work patients with type 2 diabetes mellitus (T2DM) enact and explore the interactions between illness, treatment, and life. PATIENTS AND METHODS: In this mixed-methods, descriptive study, adult patients with T2DM seen at the outpatient diabetes clinic at Mayo Clinic in Rochester, Minnesota, from February 1, 2016, through March 31, 2017, were invited to participate. The study had 3 phases. In phase 1, the Patient Experience with Treatment and Self-management (PETS) scale was used to quantify treatment burden. In phase 2, a convenience sample of patients used a smartphone application to describe, in real time, time spent completing diabetes self-management tasks and to upload descriptive digital photographs. In phase 3, these data were explored in qualitative interviews that were analyed by 2 investigators using deductive analysis. RESULTS: Of 162 participants recruited, 160 returned the survey (phase 1); of the 50 participants who used the smartphone application (phase 2), we interviewed 17 (phase 3). The areas in which patients reported highest treatment burden were difficulty with negotiating health services (eg, coordinating medical appointments), medical expenses, and mental/physical exhaustion with self-care. Participants reported that medical appointments required about 2.5 hours per day, and completing administrative tasks related to health care required about 45 minutes. Time spent on health behaviors varied widely-from 2 to 60 minutes in a given 3-hour period. Patients' experience of a task's burden did not always correlate with the time spent on that task. CONCLUSION: The most burdensome tasks to patients with T2DM included negotiating health care services, affording medications, and completing administrative tasks even though they were not the most time-consuming activities. To be minimally disruptive, diabetes care should minimize the delegation of administrative tasks to patients
- …